Skip to content
Listen: A Tussle With a Rattlesnake Can Take a Bite Out of Your Wallet

Listen: A Tussle With a Rattlesnake Can Take a Bite Out of Your Wallet

Brigland Pfeffer was bitten by a rattlesnake while playing in his San Diego backyard. After problems administering a starting dose of antivenom, emergency room staffers found a way that worked and stabilized the 2-year-old. He received 30 total vials of the antivenom Anavip. (Ariana Drehsler for KFF Health News)

After their younger son was bitten by a rattlesnake and ended up in the pediatric intensive care unit, a San Diego couple received a huge bill. Listen to hear why antivenom is so expensive.

This spring, a San Diego toddler spent two days in a pediatric intensive care unit after a rattlesnake bit his hand in his family’s backyard.

The bills that followed were staggering, with the lifesaving antivenom the 2-year-old needed accounting for more than two-thirds of the total cost — $213,000.

Why is antivenom so expensive? One explanation is the markup hospitals add to balance overhead costs and make money. Another explanation is a lack of meaningful competition. There are only two rattlesnake antivenoms approved by the Food and Drug Administration.

Stacie Dusetzina, a professor of health policy at Vanderbilt University Medical Center, said it can be difficult to sort out drug pricing because a hospital bill is often an instrument insurers and hospitals use to negotiate prices. Patients such as the Pfeffers often get stuck in the middle.

“When you see the word ‘charges,’ that’s a made-up number. That isn’t connected at all, usually, to what the actual drug cost,” Dusetzina said.

Read more here.

Toddler’s Backyard Snakebite Bills Totaled More Than a Quarter Million Dollars

For snakebite victims, antivenom is critical — and costly. It took more than $200,000 worth of antivenom to save one toddler’s life after he was bitten by a rattlesnake.

Read More

This article was produced by KFF Health News, a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF — the independent source for health policy research, polling, and journalism.